Cat.No. : CSC-RO0817 Host Cell: Ba/F3
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0817 |
| Description | Ba/F3-FGFR2-BICC1-N549K cell line is engineered to stably overexpress human FGFR2-BICC1 fusion protein bearing N549K mutation in FGFR2 part. |
| Target Gene | FGFR2-BICC1 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | Ba/F3 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Growth Conditions | 37 °C, 5% CO2 |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Biosafety Level | 2 |
| Thawing & Subculturing Instructions | 1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL. |
| Growth Properties | Suspension, round |
| Freeze Medium | Frozen with 70% medium, 20% FBS, 10% DMSO |
| Freezing Instructions | Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
A: The FGFR2-BICC1-N549K gene is a novel fusion gene identified in certain types of cancer, particularly in lung adenocarcinoma. This fusion gene results from the combination of the FGFR2 (fibroblast growth factor receptor 2) and BICC1 (BICA/MICAL complex component 1) genes, with the N549K mutation being a specific variant of FGFR2. This fusion and mutation are associated with aggressive tumor growth and poor prognosis.
A: The FGFR2-BICC1-N549K fusion gene contributes to cancer development by activating aberrant signaling pathways. The fusion event results in the constitutive activation of FGFR2, which leads to uncontrolled cell growth, invasion, and angiogenesis. The N549K mutation further enhances the oncogenic potential of FGFR2, making the fusion gene a driver of tumor progression.
A: Targeting the FGFR2-BICC1-N549K fusion gene has significant therapeutic implications. Inhibitors of FGFR signaling, such as tyrosine kinase inhibitors, may be effective in treating cancers with this fusion gene. The specific N549K mutation can also be targeted for personalized medicine approaches, potentially improving patient outcomes.
A: The FGFR2-BICC1-N549K fusion gene is detected through various molecular diagnostic techniques, such as fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR), and next-generation sequencing (NGS). These methods can identify the specific fusion event and the N549K mutation, allowing for accurate diagnosis and prognosis of patients with tumors harboring this fusion gene.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Human FGFR2-BICC1-N549K Stable Cell Line - Ba/F3 showcases exceptional editing precision, ensuring the accurate representation of the specific mutation, which is crucial for studying the impact of this alteration on cellular behavior and response to treatments.
This cell line maintains high homogeneity, with all cells uniformly expressing the FGFR2-BICC1-N549K mutation. This uniformity simplifies data interpretation and allows for consistent and reproducible experimental outcomes.
The Human FGFR2-BICC1-N549K Stable Cell Line - Ba/F3 has significant clinical relevance, providing a valuable model for understanding the biology of FGFR2-driven cancers and for testing novel therapeutic approaches that target this specific mutation.
This cell line poses no inherent biosafety risks, ensuring that researchers can work with it safely and confidently, without the need for additional containment measures, which is essential for ethical and regulatory compliance.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
